Prostate Cell News Volume 6.13 | Apr 17 2015

A Glycolytic Phenotype Is Associated with Prostate Cancer Progression and Aggressiveness: A Role for Monocarboxylate Transporters as Metabolic Targets for Therapy
Investigators demonstrated the metabolic heterogeneity of prostate cancer (PCa) and its clinical relevance. They present evidence supporting monocarboxylate transporters as suitable targets in PCa, affecting not only cancer cell proliferation and survival but also the expression of a number of hypoxia inducible factor-target genes associated with poor prognosis. [J Pathol] Abstract

Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer
Investigators showed nelfinavir and its analogs inhibited castration-resistant prostate cancer proliferation by blocking regulated intramembrane proteolysis through suppression of site-2 proteas cleavage activity. [Sci Rep] Full Article

Adiponectin as a Potential Tumor Suppressor Inhibiting Epithelial-to-Mesenchymal Transition but Frequently Silenced in Prostate Cancer by Promoter Methylation
Adiponectin (ADN) is a hormone secreted by adipose tissue and has a variety of functions including the inhibition of prostate cancer cell proliferation. 5-aza and TSA treatment restored ADN expression in LNCaP cells in which the ADN expression was almost absent. [Prostate] Abstract

Overexpression of the Novel Senescence Marker β-Galactosidase (GLB1) in Prostate Cancer Predicts Reduced PSA Recurrence
In vitro characterization of GLB1 was determined in primary prostate epithelial cell cultures passaged to replicative senescence and in therapy-induced senescence in prostate cancer lines using chemotherapeutic agents. [PLoS One] Full Article

MK591, a Second Generation Leukotriene Biosynthesis Inhibitor, Prevents Invasion and Induces Apoptosis in the Bone-Invading C4-2B Human Prostate Cancer Cells: Implications for the Treatment of Castration-Resistant, Bone-Metastatic Prostate Cancer
Investigators tested the effects of MK591, a second-generation, specific inhibitor of 5-Lox activity, on the viability and metastatic characteristics of castration-resistant prostate cancer cells. They observed that MK591 effectively kills the bone-invading C4-2B human prostate cancer cells, but does not affect normal, non-cancer fibroblasts in the same experimental conditions. [PLoS One] Full Article

The ErbB3-Binding Protein EBP1 Modulates Lapatinib Sensitivity in Prostate Cancer Cells
Scientists examined the effects of EBP1 expression on the response to the ErbB1/2 tyrosine kinase inhibitor lapatinib. They found a negative correlation between endogenous EBP1 levels and lapatinib sensitivity in prostate cancer cell lines. [Mol Cell Biochem] Abstract

CLINICAL RESEARCH

Efficacy and Safety of Docetaxel and Prednisolone for Castration-Resistant Prostate Cancer: A Multi-Institutional Retrospective Study in Japan
Scientists evaluated the efficacy and safety of docetaxel and prednisolone in patients with castration-resistant prostate cancer. A total of 140 patients with castration-resistant prostate cancer received docetaxel and prednisolone. [Jpn J Clin Oncol] Abstract

Effect of Enzalutamide on Health-Related Quality of Life, Pain, and Skeletal-Related Events in Asymptomatic and Minimally Symptomatic, Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (PREVAIL): Results from a Randomized, Phase III Trial
Researchers report the effect of enzalutamide on health-related quality of life, pain, and skeletal-related events observed during this trial. In this Phase III, double-blind trial, patients were randomly assigned to receive enzalutamide 160 mg/day or placebo orally. [Lancet Oncol] Abstract | Press Release

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

AACR Recognizes Research Team that Developed Treatment for Late-Stage Prostate Cancer
The American Association for Cancer Research (AACR) will award the ninth annual AACR Team Science Award to the Designing Androgen Receptor Inhibitors Team from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles at the AACR Annual Meeting 2015. [American Association for Cancer Research] Press Release

Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of Tasquinimod in Prostate Cancer
Active Biotech and Ipsen announced top line results of the 10TASQ10 study. While the study showed that tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo in patients with metastatic castration resistant prostate cancer who have not received chemotherapy, tasquinimod did not extend overall survival. [Active Biotech AB] Press Release

Study to Tackle Unresolved Link between Prostate Cancer Treatment and Cardiovascular Disease
Funded by the Movember Foundation and selected by Prostate Cancer Canada , Dr. Jehonathan Pinthus and his team will directly address the longstanding uncertainty regarding a connection between androgen deprivation therapy and an increased risk of cardiovascular disease. The project will receive up to $3.5 million over five years after winning the Movember Clinical Trials grant competition. [Prostate Cancer Canada] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Postdoctoral Fellow – Genitourinary Cancers (Geisinger Health System)

Cancer Biologist (Wake Forest Baptist Medical Center)

Postdoctoral Positions – Stem Cells and Cancer (Brigham & Women’s Hospital)

Postdoctoral Position – Systems Genetics of Aggressive Prostate Cancer (National Institutes of Health)

Postdoctoral Research Fellow – Prostate Cancer and Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Scientist – Prostate Cancer (Columbia University Medical Center)

Postdoctoral Fellow – Development, Progression and Chemotherapy Resistance of Cancers (University of Maryland School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.